Aurinia Pharmaceuticals Inc (AUPH) reports significant growth in Lupkynis sales and raises its 2025 sales guidance, while navigating legal and regulatory hurdles.

Aurinia's Q3 2025 saw 27% LUPKYNIS sales growth and raised 2025 guidance. Discover key earnings insights, clinical updates, and pipeline progress.

Aurinia Pharmaceuticals (AUPH) stock gains as the company's Q3 2025 results beat forecasts despite an FDA information request ...

Aurinia Pharmaceuticals ( ($AUPH) ) has issued an update. Aurinia Pharmaceuticals reported a significant increase in financial performance for the ...

Aurinia Pharmaceuticals (($AUPH)) has held its Q3 earnings call. Read on for the main highlights of the call. Aurinia Pharmaceuticals’ recent ...

The resignation of head drug regulator George Tidmarsh comes amid concerns about conduct related to the lupus nephritis drug ...

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe ...